Ciccarese, Chiara
 Distribuzione geografica
Continente #
EU - Europa 1.536
NA - Nord America 1.156
AS - Asia 710
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 4
SA - Sud America 3
Totale 3.414
Nazione #
US - Stati Uniti d'America 1.153
GB - Regno Unito 621
CN - Cina 460
SG - Singapore 180
IT - Italia 172
SE - Svezia 171
IE - Irlanda 145
RU - Federazione Russa 133
FR - Francia 98
DE - Germania 95
FI - Finlandia 45
VN - Vietnam 24
UA - Ucraina 13
NL - Olanda 10
KR - Corea 9
BE - Belgio 8
AT - Austria 7
IN - India 6
ID - Indonesia 5
EU - Europa 4
TR - Turchia 4
BR - Brasile 3
GR - Grecia 3
JP - Giappone 3
LK - Sri Lanka 3
LT - Lituania 3
PH - Filippine 3
PL - Polonia 3
AZ - Azerbaigian 2
BD - Bangladesh 2
CA - Canada 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
HU - Ungheria 2
TG - Togo 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
CR - Costa Rica 1
IL - Israele 1
JO - Giordania 1
KG - Kirghizistan 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
PK - Pakistan 1
SA - Arabia Saudita 1
SN - Senegal 1
Totale 3.414
Città #
Southend 609
Chandler 300
Singapore 162
Dublin 145
Woodbridge 105
Beijing 100
Ann Arbor 74
Ashburn 62
Houston 54
Lawrence 46
Princeton 46
Jacksonville 44
Nanjing 41
Wilmington 38
Jinan 31
Shenyang 26
Verona 21
Hebei 19
New York 16
Helsinki 15
Redwood City 14
Changsha 13
Dong Ket 13
Haikou 13
Sindelfingen 13
Tianjin 13
Zhengzhou 13
Guangzhou 12
Santa Clara 10
Taizhou 10
Jiaxing 9
Bologna 8
Brussels 8
Dearborn 8
Milan 8
Ningbo 8
Norwalk 8
Seoul 8
Fuzhou 7
Kent 7
Moscow 7
Nanchang 7
Vienna 7
Lanzhou 6
Taiyuan 6
Hangzhou 5
Jakarta 5
Los Angeles 5
Rome 5
Seattle 5
Bussolengo 4
Catanzaro 4
Fairfield 4
Groningen 4
Trento 4
Athens 3
Colombo 3
Dallas 3
Detroit 3
Frankfurt am Main 3
London 3
Nave 3
Renton 3
São Paulo 3
Washington 3
Baku 2
Boardman 2
Büdelsdorf 2
Dhaka 2
Hefei 2
Lancaster 2
Lausanne 2
Lomé 2
Ludhiana 2
Novara 2
Nürnberg 2
Osio Sotto 2
Padova 2
Prague 2
Tokyo 2
Venezia 2
Volargne 2
Wuhan 2
Amman 1
Austin 1
Bakersfield 1
Bangkok 1
Bergamo 1
Bishkek 1
Cascina 1
Chaoyang 1
Chicago 1
Clearwater 1
Clifton 1
Dakar 1
Fremont 1
Islamabad 1
Kemerovo 1
Kochi 1
Lappeenranta 1
Totale 2.318
Nome #
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 121
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 120
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 112
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 107
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 106
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 104
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 103
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 102
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 96
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 94
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? 93
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 93
Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice 92
The route to personalized medicine in bladder cancer: where do we stand? 86
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 85
AR-V7 and prostate cancer: The watershed for treatment selection? 83
The development of PARP as a successful target for cancer therapy 83
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 80
Metabolic phenotype of bladder cancer 78
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 78
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 76
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research 75
Metabolic alterations in renal cell carcinoma 75
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 73
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 71
2015 and human cancer: back to overall survival 70
Inside the 2015 ASCO Genitourinary Cancers Symposium 70
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 69
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma 64
Acquired hemophagocytic syndrome: comment to the case report 63
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives 62
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer 61
Bladder cancer: molecular determinants of personalized therapy 60
Metabolic Alterations in Renal and Prostate Cancer 59
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer 59
Kidney cancer and 2014: is innovation really over? 55
The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer 55
Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR? 54
Role of STAT3 pathway in genitourinary tumors 53
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 52
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 50
Emerging Immunotargets in Bladder Cancer 50
The prospect of precision therapy for renal cell carcinoma 48
Tp53 and its potential therapeutic role as a target in bladder cancer 46
Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis 37
Present and future of personalized medicine in adult genitourinary tumors 34
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer 26
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story 12
Totale 3.495
Categoria #
all - tutte 13.684
article - articoli 13.684
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.368


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020174 0 0 0 0 0 0 60 12 20 26 16 40
2020/2021300 38 48 18 73 38 17 11 3 2 7 20 25
2021/2022282 15 66 2 32 23 8 3 21 10 8 11 83
2022/2023827 54 96 72 136 59 221 2 62 93 11 17 4
2023/2024357 13 34 25 32 75 36 10 39 5 18 60 10
2024/2025453 48 54 51 234 27 37 2 0 0 0 0 0
Totale 3.495